Review Article
Risk of Malignant Neoplasia with Glucagon-Like Peptide-1 Receptor Agonist Treatment in Patients with Type 2 Diabetes: A Meta-Analysis
Figure 2
Meta-analysis of the incidence of neoplasms with the use of all tested GLP-1 receptor agonists versus placebo or other antidiabetic treatments.